Pleconaril

Pleconaril is an antipicornaviral agent.^1,2 It inhibits Picornaviridae viral replication by binding to a hydrophobic pocket in the major VP1 capsid protein, which prevents uncoating of the viral RNA genome. Pleconaril inhibits replication of the rhinoviruses HRV-A2 and HRV-B14 in HeLa Rh cells (EC₅₀s = 0.1 and 0.3 μM, respectively) and is not cytotoxic to HeLa Rh cells with a 50% cytotoxic concentration (CC₅₀) of greater than 131 μM.³ It also inhibits replication of enterovirus 71 (EV71) in human rhabdomyosarcoma (RD) cells (EC₅₀ = 15 μM) and is not cytotoxic to RD cells (CC₅₀ = >131 μM). Pleconaril (80 mg/kg per day) increases survival of EV71-infected mouse pups from 20 to 80%.⁴

WARNING This product is not for human or veterinary use.

1. Florea, N.R., Maglio, D., and Nicolau, D.P. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy 23(3), 339-348 (2003).

2. Bernard, A., Lacroix, C., Cabiddu, M.G., et al. Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. Antivir. Chem. Chemother. 24(2), 56-61 (2015).

3. Zhang, G., Zhou, F., Gu, B., et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch. Virol. 157(4), 669-679 (2012).